Cytori Therapeutics Inc (CYTX) 0.47 $CYTX
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Open label trial begins to assess Cytori Cell Therapy in meniscal injuries
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 7:49AM CST
CYTX: 0.47 (unch)
Enrollment Begins European Knee Meniscus Injury Pilot Trial to Evaluate Cytori Cell Therapy
Business Wire - Tue Feb 10, 7:02AM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the first patient was enrolled and treated this week in a single arm, open label investigator initiated trial of Cytori Cell Therapy in patients undergoing surgery for traumatic meniscal injuries in the knee.
CYTX: 0.47 (unch)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Cytori and Leading Expert Discuss Importance of 'STAR' Trial and Treatment for Scleroderma Patients
Business Wire - Tue Jan 20, 3:15PM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that information, presented last week in San Francisco, introducing its pivotal scleroderma trial ("the STAR trial"
, is now available on the company website at www.Cytori.com. The information session featured Dr. Dinesh Khanna, Frederick G.L. Huetwell Professor of Rheumatology and Associate Professor of Internal Medicine in the Division of Rheumatology, and Director of the Scleroderma Program at the University of Michigan (med.umich.edu/scleroderma). Dr. Khanna is the Principal Investigator of Cytori's STAR Trial. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 "Best Doctor of the Year" award from the Scleroderma Foundation.
CYTX: 0.47 (unch)
FDA Approves Cytori U.S. Pivotal Scleroderma Trial
Business Wire - Mon Jan 12, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the Center for Biologics Evaluation and Research (CBER), a division of the U.S. Food and Drug Administration (FDA), has given final approval to its application for an Investigational Device Exemption (IDE) to begin a pivotal trial (the "STAR trial" to evaluate Cytori Cell Therapy(TM) as a potential treatment for impaired hand function in scleroderma.
CYTX: 0.47 (unch)
Turnaround potential? 2014's worst performers in the Russell 2000
Seeking Alpha - at Seeking Alpha - Sun Jan 04, 2:49PM CST
KWK: 0.15 (unch), BPZ: 0.25 (unch), EXXI: 4.00 (+0.42), MBII: 3.88 (+0.33), MILL: 2.07 (+0.09), PHMD: 1.68 (+0.04), PRKR: 1.07 (+0.04), RLOC: 3.58 (+0.42), NTLS: 5.19 (+0.05), VTG: 0.52 (-0.02), GDP: 3.58 (+0.29), REN: 1.14 (unch), CYTX: 0.47 (unch), XONE: 16.93 (-0.16), KEG: 2.14 (+0.08), REXX: 5.08 (+0.13), AMZG: 0.65 (-0.03), COVS: 2.47 (+0.11), EXEL: 2.48 (+0.20), ANV: 0.97 (-0.03), VRNG: 0.81 (+0.01), FUEL: 14.30 (+0.65), ZQK: 2.26 (+0.05), GALT: 3.84 (+0.16), EOX: 1.15 (unch), SALT: 2.17 (+0.18), MM: 1.67 (+0.07), WLT: 1.09 (+0.05), NADL: 2.10 (-0.02), QRHC: 1.30 (+0.03), MCP: 0.97 (+0.04), ANR: 1.27 (+0.03), ARO: 3.63 (+0.04), RGDO: 1.17 (+0.02), HERO: 0.92 (+0.02), FWM: 5.55 (+0.08), CONN: 24.69 (-0.07), MPO: 1.00 (-0.02), CVEO: 3.87 (+0.15), SZYM: 2.64 (+0.02)
Cytori and BARDA amend contract for development of thermal burn cell therapy
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 6:45AM CST
CYTX: 0.47 (unch)
Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury Countermeasure
Business Wire - Fri Dec 19, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX) today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, executed an amendment of a contract option originally signed in August 2014 to fund continued investigation and development of Cytori Cell Therapy(TM) for use in thermal burn injuries.
CYTX: 0.47 (unch)
Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal Investigator, Dr. Dinesh Khanna
Business Wire - Thu Dec 18, 4:39PM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an information session dedicated to its planned STAR pivotal trial and scleroderma, featuring principal investigator Dr. Dinesh Khanna. The session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736.
CYTX: 0.47 (unch)
Stock to Watch: Cytori Therapeutics Up 5.7% (CYTX)
Comtex SmarTrend(R) - Thu Dec 18, 12:48PM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 5.7% to $0.52 on 1.0x average daily volume. Thus far today, Cytori Therapeutics has traded 1.6 million shares, vs. average volume of 1.5 million shares per day. The stock has outperformed the Dow (5.7% to the Dow's 1.7%) and outperformed the S&P 500 (5.7% to the S&P's 1.8%) during today's trading.
CYTX: 0.47 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Cytori to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco
Business Wire - Wed Dec 17, 6:25PM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company has been selected to present at the Biotech Showcase(TM) at 3:30 PM Pacific Time (6:30 PM Eastern Time) on Monday, January 12, 2015. The presentation will take place in the C-Mission II room at the Parc 55 Wyndham Hotel in San Francisco.
CYTX: 0.47 (unch)
Cytori Therapeutics Up 6.2%, Penny Stock Attracts Attention (CYTX)
Comtex SmarTrend(R) - Wed Dec 10, 10:05AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 6.2% to $0.49 on 2.1x average daily volume. Thus far today, Cytori Therapeutics has traded 3.0 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (7.3% to the Dow's -0.6%) and outperformed the S&P 500 (7.3% to the S&P's -0.5%) during today's trading.
CYTX: 0.47 (unch)
FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma
Business Wire - Wed Dec 10, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the 'STAR' trial, to evaluate Cytori Cell Therapy(TM) as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
CYTX: 0.47 (unch)
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing
CNW Group - Fri Dec 05, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX), today announced that the presentation and corporate update given on December 4 by President and CEO Marc Hedrick, M.D. is now available for on-demand viewing at VirtualInvestorConferences.com.
CYTX: 0.47 (unch)
Cytori says new Japanese regen laws should goose Celution sales
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:14PM CST
CYTX: 0.47 (unch)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Open label trial begins to assess Cytori Cell Therapy in meniscal injuries
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 7:49AM CST
CYTX: 0.47 (unch)
Enrollment Begins European Knee Meniscus Injury Pilot Trial to Evaluate Cytori Cell Therapy
Business Wire - Tue Feb 10, 7:02AM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the first patient was enrolled and treated this week in a single arm, open label investigator initiated trial of Cytori Cell Therapy in patients undergoing surgery for traumatic meniscal injuries in the knee.
CYTX: 0.47 (unch)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Cytori and Leading Expert Discuss Importance of 'STAR' Trial and Treatment for Scleroderma Patients
Business Wire - Tue Jan 20, 3:15PM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that information, presented last week in San Francisco, introducing its pivotal scleroderma trial ("the STAR trial"
, is now available on the company website at www.Cytori.com. The information session featured Dr. Dinesh Khanna, Frederick G.L. Huetwell Professor of Rheumatology and Associate Professor of Internal Medicine in the Division of Rheumatology, and Director of the Scleroderma Program at the University of Michigan (med.umich.edu/scleroderma). Dr. Khanna is the Principal Investigator of Cytori's STAR Trial. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 "Best Doctor of the Year" award from the Scleroderma Foundation. CYTX: 0.47 (unch)
FDA Approves Cytori U.S. Pivotal Scleroderma Trial
Business Wire - Mon Jan 12, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the Center for Biologics Evaluation and Research (CBER), a division of the U.S. Food and Drug Administration (FDA), has given final approval to its application for an Investigational Device Exemption (IDE) to begin a pivotal trial (the "STAR trial"
to evaluate Cytori Cell Therapy(TM) as a potential treatment for impaired hand function in scleroderma. CYTX: 0.47 (unch)
Turnaround potential? 2014's worst performers in the Russell 2000
Seeking Alpha - at Seeking Alpha - Sun Jan 04, 2:49PM CST
KWK: 0.15 (unch), BPZ: 0.25 (unch), EXXI: 4.00 (+0.42), MBII: 3.88 (+0.33), MILL: 2.07 (+0.09), PHMD: 1.68 (+0.04), PRKR: 1.07 (+0.04), RLOC: 3.58 (+0.42), NTLS: 5.19 (+0.05), VTG: 0.52 (-0.02), GDP: 3.58 (+0.29), REN: 1.14 (unch), CYTX: 0.47 (unch), XONE: 16.93 (-0.16), KEG: 2.14 (+0.08), REXX: 5.08 (+0.13), AMZG: 0.65 (-0.03), COVS: 2.47 (+0.11), EXEL: 2.48 (+0.20), ANV: 0.97 (-0.03), VRNG: 0.81 (+0.01), FUEL: 14.30 (+0.65), ZQK: 2.26 (+0.05), GALT: 3.84 (+0.16), EOX: 1.15 (unch), SALT: 2.17 (+0.18), MM: 1.67 (+0.07), WLT: 1.09 (+0.05), NADL: 2.10 (-0.02), QRHC: 1.30 (+0.03), MCP: 0.97 (+0.04), ANR: 1.27 (+0.03), ARO: 3.63 (+0.04), RGDO: 1.17 (+0.02), HERO: 0.92 (+0.02), FWM: 5.55 (+0.08), CONN: 24.69 (-0.07), MPO: 1.00 (-0.02), CVEO: 3.87 (+0.15), SZYM: 2.64 (+0.02)
Cytori and BARDA amend contract for development of thermal burn cell therapy
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 6:45AM CST
CYTX: 0.47 (unch)
Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury Countermeasure
Business Wire - Fri Dec 19, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX) today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, executed an amendment of a contract option originally signed in August 2014 to fund continued investigation and development of Cytori Cell Therapy(TM) for use in thermal burn injuries.
CYTX: 0.47 (unch)
Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal Investigator, Dr. Dinesh Khanna
Business Wire - Thu Dec 18, 4:39PM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an information session dedicated to its planned STAR pivotal trial and scleroderma, featuring principal investigator Dr. Dinesh Khanna. The session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736.
CYTX: 0.47 (unch)
Stock to Watch: Cytori Therapeutics Up 5.7% (CYTX)
Comtex SmarTrend(R) - Thu Dec 18, 12:48PM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 5.7% to $0.52 on 1.0x average daily volume. Thus far today, Cytori Therapeutics has traded 1.6 million shares, vs. average volume of 1.5 million shares per day. The stock has outperformed the Dow (5.7% to the Dow's 1.7%) and outperformed the S&P 500 (5.7% to the S&P's 1.8%) during today's trading.
CYTX: 0.47 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Cytori to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco
Business Wire - Wed Dec 17, 6:25PM CST
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company has been selected to present at the Biotech Showcase(TM) at 3:30 PM Pacific Time (6:30 PM Eastern Time) on Monday, January 12, 2015. The presentation will take place in the C-Mission II room at the Parc 55 Wyndham Hotel in San Francisco.
CYTX: 0.47 (unch)
Cytori Therapeutics Up 6.2%, Penny Stock Attracts Attention (CYTX)
Comtex SmarTrend(R) - Wed Dec 10, 10:05AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing penny stocks, up 6.2% to $0.49 on 2.1x average daily volume. Thus far today, Cytori Therapeutics has traded 3.0 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (7.3% to the Dow's -0.6%) and outperformed the S&P 500 (7.3% to the S&P's -0.5%) during today's trading.
CYTX: 0.47 (unch)
FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma
Business Wire - Wed Dec 10, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the 'STAR' trial, to evaluate Cytori Cell Therapy(TM) as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
CYTX: 0.47 (unch)
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing
CNW Group - Fri Dec 05, 7:00AM CST
Cytori Therapeutics (NASDAQ: CYTX), today announced that the presentation and corporate update given on December 4 by President and CEO Marc Hedrick, M.D. is now available for on-demand viewing at VirtualInvestorConferences.com.
CYTX: 0.47 (unch)
Cytori says new Japanese regen laws should goose Celution sales
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:14PM CST
CYTX: 0.47 (unch)
